Hepatocellular Carcinoma Risk Stratification by Genetic Profiling in Patients with Cirrhosis

Naoto Fujiwara, Yujin Hoshida

Research output: Contribution to journalArticle

Abstract

Prediction of future hepatocellular carcinoma (HCC) risk in the sizable chronic liver disease population is an urgent unmet need to enable regular HCC screening for early detection. Germline deoxyribonucleic acid polymorphisms likely represent etiology-specific host factors that determine HCC susceptibility, including single nucleotide polymorphisms in EGF, IFNL3, MICA, and TLL1 in hepatitis C with or without active viral infection, and PNPLA3, TM6SF2, and MBOAT7 in metabolic liver diseases. Transcriptome-based prognostic liver signature in diseased liver tissue has been associated with long-term HCC risk in viral and metabolic etiologies. Transcriptomic signatures of hepatic injury and specific cell type such as aggregated lymphocytes also predict HCC development. Circulating factors such as proteins and their chemical modification, nucleotides, and metabolites may serve for less-invasive assessment of short-or long-term HCC risk. These biomarkers will enable individual HCC risk-based personalized clinical management for cost-effective early HCC detection and improvement of patient survival.

Original languageEnglish (US)
Pages (from-to)153-162
Number of pages10
JournalSeminars in Liver Disease
Volume39
Issue number2
DOIs
StatePublished - Jan 1 2019

    Fingerprint

Keywords

  • cirrhosis
  • hepatocellular carcinoma
  • precision medicine
  • Risk prediction

ASJC Scopus subject areas

  • Hepatology

Cite this